Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

  • In development
  • GID-TA11613
  • Expected publication date: TBC

 

 

Notice of Appeal

Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

 

NICE has received 2 appeals, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:

 

  • Ipsen Limited
  • Neuroendocrine Cancer UK

 

The appeal panel will convene on Wednesday 24 June 2026 at 10:00am via Zoom to hear oral representations from the appellants.

 

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

 

Where possible, requests to attend should be made using the registration link that will be available on our website from Friday 15 May 2026. The registration period for this appeal will end at 4:00pm on Wednesday 17 June.

 

Further details relating to public attendance at this appeal are available on the same webpage as above.